China Pharma Holdings (CPHI)
(Real Time Quote from BATS)
$0.22 USD
-0.01 (-2.61%)
Updated Sep 19, 2024 03:32 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for China Pharma Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 7 | 8 | 10 | 11 | 11 |
Cost Of Goods | 7 | 9 | 9 | 9 | 9 |
Gross Profit | 0 | 0 | 0 | 2 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 2 | 3 | 3 | 5 | 22 |
Income After Depreciation & Amortization | -3 | -4 | -3 | -3 | -20 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 1 | 0 | 0 |
Pretax Income | -3 | -4 | -3 | -3 | -21 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -3 | -4 | -3 | -3 | -21 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -3 | -4 | -3 | -3 | -21 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -1 | 0 | 0 | -17 |
Depreciation & Amortization (Cash Flow) | 3 | 3 | 3 | 3 | 3 |
Income After Depreciation & Amortization | -3 | -4 | -3 | -3 | -20 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 3.38 | 1.05 | 0.92 | 0.87 | 0.87 |
Diluted EPS Before Non-Recurring Items | -0.91 | -3.80 | -3.50 | -3.50 | -24.00 |
Diluted Net EPS (GAAP) | -0.91 | -3.80 | -3.50 | -3.50 | -24.00 |
Fiscal Year end for China Pharma Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.92 | 1.37 | 2.15 | 1.80 | 1.10 |
Cost Of Goods | 1.94 | 1.66 | 2.23 | 2.04 | 1.24 |
Gross Profit | -1.02 | -0.29 | -0.08 | -0.23 | -0.15 |
SG&A, R&D, and Dept/Amort Expenses | 0.37 | 0.62 | 1.11 | 0.48 | 0.31 |
Income After SG&A, R&D, and Dept/Amort Expenses | -1.39 | -0.91 | -1.19 | -0.71 | -0.46 |
Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 0.05 | 0.04 | 0.05 | 0.07 | 0.14 |
Pretax Income | -1.44 | -0.96 | -1.23 | -0.78 | -0.59 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -1.44 | -0.96 | -1.23 | -0.78 | -0.59 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -1.44 | -0.96 | -1.23 | -0.78 | -0.59 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 16.12 | 13.13 | NA | 2.64 | 1.98 |
Diluted EPS Before Non-Recurring Items | -0.09 | -0.07 | NA | -0.30 | -0.30 |
Diluted Net EPS (GAAP) | -0.09 | -0.07 | -0.01 | -0.30 | -0.30 |